Keyword: GW Pharmaceuticals
GW Pharma just won the industry's first cannabinoid nods from NICE, which endorsed Epidyolex for a rare epilepsy and Sativex for MS muscle spasticity.
Despite solid Epidiolex sales, investors are punishing GW Pharma. Could they have overlooked new data key to the cannabinoid drug's future?
As drugmakers dip their toes into the water of cannabis-based drugs, major companies have been shy to join. Now, a Teva subsidiary wants in.
At its July meeting, experts with the European Medicines Agency's CHMP recommended approvals for four novel drugs, a Mylan generic and more.
GW Pharma created a virtual reality voyage to allow doctors to see for themselves its pharma-quality growing operations and process.
Epidiolex posted sales more than twice what was expected in Q1, but thanks to some "unusual launch dynamics," the numbers could slow.
GW Pharma may be the first drugmaker to launch a cannabis-based drug in the U.S., but it's unlikely to be the last—and that's why so many are watching.
What's on Tuesday's talking points memo at JPM? Drug launches, hoped-for FDA nods, deals, rivalries, FDA tea leaves—and one unexpected tax bill.
FSD Pharma taps competing prescription CBD company GW Pharma’s former top marketing executive to serve as its new CEO.
The first FDA-approved CBD product launched Thursday in the form of GW Pharmaceuticals' cannabinoid Epidiolex, which treats rare epilepsy.